Diabetes Therapies and Diagnostics: Global Markets

Diabetes Therapies and Diagnostics: Global Markets

BCC's goal in conducting this study was to determine the current status of the global diabetes market and assess its growth potential over a 5-year period from 2008 to 2013. Of particular interest were the market segment position of the diagnostics and therapeutics in relation to management of diabetic condition and diabetic complications for the fast growing global diabetic community, if the prediction of global epidemic prevalence of type II diabetes population is fulfilled.

In addition, BCC was interested in the market potential for new insulin infusion pumps, non-invasive insulin delivery methods, and the new class of incretin mimetics therapeutics for diabetes treatment as well as technology innovation for management of diabetes and diabetic complications.

The key objective was to present a comprehensive analysis of the current diabetes market and its future direction to meet the unmet demands of diabetic consumers. 
 

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED REPORTS

BCC ONLINE SERVICES

DISCLAIMER

SUMMARY

SUMMARY TABLE GLOBAL DIABETES MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ BILLIONS)

SUMMARY FIGURE GLOBAL DIABETES MARKET FORECAST BY SEGMENT, 2006-2013 ($ BILLIONS)

OVERVIEW

OVERVIEW

TABLE 1 PREVALENCE OF TYPE I AND II DIABETES: TOP SIX COUNTRIES WITH HIGH GROWTH PROJECTIONS, THROUGH 2013 (MILLIONS)

TABLE 2 PREVALENCE OF TYPE II DIABETES: TOP SIX COUNTRIES WITH PROJECTIONS, THROUGH 2013 (MILLIONS)

TABLE 3 DEFINITIONS OF THE FOUR TYPES OF DIABETES

TABLE 3 (CONTINUED)

TABLE 4 SUMMARY OF DIABETES PRODUCTS AND APPLICATIONS

DIABETES DISEASE

CAUSATION, RISK FACTORS, AND COMPLICATIONS

TABLE 5 CAUSAL OR RISK FACTORS BY DIABETES TYPE

TABLE 6 COMPLICATIONS BY TYPE OF DIABETES

DIABETES MANAGEMENT

DIABETES MANAGEMENT (CONTINUED)

DIABETES MANAGEMENT (CONTINUED)

DIABETES PRODUCT SEGMENTS

CONTINUOUS GLUCOSE MONITORING SYSTEMS (CGMS)

CONTINUOUS GLUCOSE MONITORING … (CONTINUED)

TABLE 7 FDA APPROVED CONTINUOUS GLUCOSE MONITORING SYSTEMS BY MANUFACTURER

INSULIN INFUSION PUMPS

TABLE 8 FDA APPROVED INSULIN INFUSION PUMPS BY MANUFACTURER

TABLE 9 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION PUMPS, THROUGH 2013 ($ MILLIONS)

FIGURE 1 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION PUMPS, 2006-2013 ($ MILLIONS)

INSULIN-DEPENDENT DRUGS

TABLE 10 TECHNOLOGICAL EVOLUTION OF INSULIN DELIVERY METHODS

TABLE 11 FDA APPROVED INSULIN-DEPENDENT PRODUCTS BY MARKET LEADER

INSULIN-DEPENDENT DRUGS (CONTINUED)

TABLE 12 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER, THROUGH 2013 ($ MILLIONS)

FIGURE 2 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER, 2006-2013 ($ MILLIONS)

INSULIN-INDEPENDENT DRUGS

TABLE 13 THE SEVEN CLASSES OF TYPE II DIABETES DRUGS

TABLE 13 (CONTINUED)

SULFONYLUREAS

TABLE 14 FDA APPROVED BRAND-NAME SULFONYLUREA DRUGS BY DRUGMAKER

TABLE 14 (CONTINUED)

BIGUANIDES

TABLE 15 FDA APPROVED BRAND-NAME BIGUANIDE DRUGS

ALPHA-GLUCOSIDASE INHIBITORS

TABLE 16 FDA APPROVED BRAND-NAME ALPHA-GLUCOSIDASE INHIBITOR DRUGS

MEGLITINIDES

TABLE 17 FDA APPROVED BRAND-NAME MEGLITINIDE DRUGS

THIAZOLIDINEDIONES (TZD)

TABLE 18 FDA APPROVED BRAND-NAME THIAZOLIDINEDIONES DRUGS

INCRETIN MIMETICS

TABLE 19 FDA APPROVED BRAND-NAME INCRETIN MIMETICS DRUGS

DIPEPTIDYL PEPTIDASE 4 (DPP-4)

TABLE 20 FDA APPROVED BRAND-NAME DPP-4 DRUGS

TABLE 21 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST, THROUGH 2013 ($ MILLIONS)

FIGURE 3 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST, 2006-2013 ($ MILLIONS)

SURGICAL TREATMENT OF DIABETES

TABLE 22 THE MARKET FOR NEW CLASSES OF DIABETES TREATMENTS

DIABETIC COMPLICATIONS MARKET

RETINOPATHY (EYE DISEASE)

NEUROPATHY (NERVE DISEASE)

NEPHROPATHY (KIDNEY DISEASE)

ARTERIOSCLEROSIS (CARDIOVASCULAR DISEASE)

OTHER COMPLICATIONS

PRESCRIPTION DRUGS FOR DIABETES COMPLICATIONS

CHOLESTEROL DRUGS

Torcetrapib (Pfizer)

HYPERTENSION DRUGS

Exforge (Novartis)

Tekturna (Novartis)

CORONARY INTERVENTION

Effient (Eli Lilly/Daiichi Sankyo)

TABLE 23 DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS, BY MANUFACTURER

TABLE 24 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, THROUGH 2013 ($ MILLIONS)

FIGURE 4 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, 2006-2013 ($ MILLIONS)

GENERIC ANTIDIABETIC DRUG MARKET

GENERIC ANTIDIABETIC DRUG MARKET

TABLE 25 FDA APPROVED GENERIC SULFONYLUREAS BY MANUFACTURER

TABLE 25 (CONTINUED)

TABLE 26 FDA APPROVED GENERIC BIGUANIDES BY MANUFACTURER

TABLE 27 FDA APPROVED GENERIC MEGLITINIDES BY MANUFACTURER

TABLE 28 FDA APPROVED GENERIC THIAZOLIDINEDIONES, BY MANUFACTURER

TABLE 29 TOP SELLING GENERIC ANTIDIABETIC DRUG FORECAST, THROUGH 2013 ($ MILLIONS)

DIABETES DRUGS IN DEVELOPMENT

CLINICAL TRIALS PHASES I-IV

PHASE I CLINICAL TRIALS ON DIABETES DRUGS

TABLE 30 DIABETES DRUGS IN PHASE I CLINICAL TRIALS

PHASE II CLINICAL TRIALS ON DIABETES DRUGS

TABLE 31 DIABETES DRUGS IN PHASE II CLINICAL TRIALS

PHASE III CLINICAL TRIALS ON DIABETES DRUGS

TABLE 32 DIABETES DRUGS IN PHASE III CLINICAL TRIALS

PHASE IV CLINICAL TRIALS ON DIABETES DRUGS

TABLE 33 DIABETES DRUGS IN PHASE IV CLINICAL TRIALS

COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS

TABLE 34 COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS

COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS

TABLE 35 COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS

COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPES OF DIABETES

TABLE 36 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPE I AND TYPE II DIABETES

PHASE I CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS

TABLE 37 PHASE I CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

PHASE II CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS

TABLE 38 PHASE II CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

PHASE III CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS

TABLE 39 PHASE III CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

PHASE IV CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS

TABLE 40 PHASE IV CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

TABLE 41 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

INCRETIN MIMETICS

PRAMLINTIDE

EXENATIDE

LIRAGLUTIDE (PHASE III)

DPP-4 INHIBITORS

VILDAGLIPTIN

SITAGLIPTIN

GLITAZARS (DUAL-PPAR AGONISTS)

MURAGLITAZAR

PATENT ANALYSIS OF DIAGNOSTIC AND THERAPEUTIC DIABETES TREATMENTS

TABLE 42 WORLDWIDE SHARES OF PATENTS AND PUBLISHED PATENT APPLICATIONS ON TYPE I AND TYPE II DIABETES TREATMENTS BY SELECTED COUNTRY, 1/1/2001-11/1/2007 (NUMBER)

U.S. AND EUROPEAN PATENTS ON TYPE I DIABETES TREATMENTS

TABLE 43 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE I DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

U.S. AND EUROPEAN PATENTS ON TYPE II DIABETES TREATMENTS

TABLE 44 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE II DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991 TO 11/30/2007 (NUMBER)

TABLE 45 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 46 U.S. AND EUROPEAN SHARES OF PATENTS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 47 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SITAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 48 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON VILDAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 49 U.S. PATENT SHARES OF VILDAGLIPTIN BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 50 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SAXAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 51 U.S. PATENT SHARES OF LIRAGLUTIDE BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 52 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON TESAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 53 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON MURAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

U.S. AND EUROPEAN PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS

TABLE 54 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS, 1/1/1991-11/30/2007 (NUMBER)

U.S. AND EUROPEAN PATENTS ON INSULIN INFUSION PUMPS

TABLE 55 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN INFUSION PUMPS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

U.S. AND EUROPEAN PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS

TABLE 56 U.S. AND EUROPEAN SHARES OF PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 57 U.S. AND EUROPEAN SHARES OF PATENTS ON BLOOD GLUCOSE METERS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

INSULIN INHALER MARKET

DRUGMAKERS DEVELOPING INHALABLE INSULIN

PFIZER

ABBOTT LABORATORIES AND KOS PHARMACEUTICALS

ELI LILLY & CO. AND ALKERMES

MANNKIND CORP

NOVO NORDISK AND ARADIGM

BAXTER INTERNATIONAL

NASTECH PHARMACEUTICAL CO.

GENEREX BIOTECHNOLOGY

TABLE 58 INHALED INSULIN PRODUCTS UNDER DEVELOPMENT BY COMPANY

INSULIN INFUSION PUMP MARKET

INSULIN INFUSION PUMP MARKET

INSULIN INFUSION PUMP MARKET (CONTINUED)

INSULIN INFUSION PUMP MARKET (CONTINUED)

INSULIN INFUSION PUMP MARKET (CONTINUED)

INSULIN DISPENSING PATCH MARKET

INSULIN DISPENSING PATCH MARKET

TABLE 59 INSULIN DISPENSING PATCHES BY MANUFACTURER

COMPANY PROFILES

ABBOTT LABORATORIES, INC

ABBOTT DIABETES CARE, INC.

ACTAVIS

ACTAVIS U.S.

ALIZYME, PLC

ALKERMES INC.

ALKERMES INC. (CONTINUED)

AMYLIN PHARMACEUTCIALS, INC.

ARADIGM CORP

ASTELLA PHARMACEUTICALS

ASTRAZENECA, PLC

ASTRAZENECA U.S

AstraZeneca U.S. (Continued)

BARR PHARMACEUTICALS, INC

BARR PHARMACEUTICALS, INC. (CONTINUED)

BAYER SCHERING PHARMA AG

BAYER HEALTHCARE PHARMACEUTICALS U.S.

BAYER GLOBAL HEALTHCARE DIABETES CARE

Bayer Global HealthCare Diabetes Care (Continued)

Bayer Global HealthCare Diabetes Care (Continued)

BRISTOL-MYERS SQUIBB CO

BRISTOL-MYERS SQUIBB CO. (CONTINUED)

CARACO PHARMA LABS, LTD

DAIICHI-SANKYO, LTD

DAIICHI-SANKYO, INC.

Daiichi-Sankyo, Inc. (Continued)

DEBIOTECH

DEPOMED, INC.

DEPOMED, INC. (CONTINUED)

DEXCOM

DR. REDDY’S LABORATORIES, LTD

DR. REDDY’S LABORATORIES, LTD.

ELI LILLY & CO

ELI LILLY & CO. (CONTINUED)

ELI LILLY & CO. (CONTINUED)

ELI LILLY & CO. (CONTINUED)

GLAXOSMITHKLINE, PLC

GLAXOSMITHKLINE

INSULET CORP.

JOHNSON & JOHNSON CO

LIFESCAN, INC

KERYX BIOPHARMACEUTICALS INC

MANNKIND CORP.

MANNKIND CORP. (CONTINUED)

MEDTRONIC INC.

MEDTRONIC DIABETES

Medtronic Diabetes (Continued)

MERCK & CO., INC.

MERCK & CO., INC. (CONTINUED)

MYLAN, INC

NOVARTIS AG

NOVARTIS U.S.

Novartis U.S. (Continued)

NOVO NORDISK A/S

NOVO NORDISK U.S

Novo Nordisk U.S. (Continued)

PAR PHARMACEUTICAL COMPANIES, INC.

PFIZER, INC

RANBAXY LABORATORIES, INC

RANBAXY U.S.

ROCHE DIAGNOSTICS CORP.

SANDOZ (NOVARTIS GENERIC DIVISION)

SANDOZ U.S.

SANOFI-AVENTIS A.G

SANOFI-AVENTIS U.S., LLC

Sanofi-Aventis U.S., LLC (Continued)

SANTHERA PHARMACEUTICALS

SMITHS MEDICAL

SMITHS MEDICAL ASD, INC

TAKEDA PHARMACEUTICAL CO., LTD

TEVA PHARMACEUTICALS, INC.

TEVA PHARMACEUTICALS USA

WATSON LABORATORIES, INC

WYETH

WYETH (CONTINUED)

LIST OF TABLES

SUMMARY TABLE GLOBAL DIABETES MARKET FORECAST BY

SEGMENT, THROUGH 2013 ($ BILLIONS)

TABLE 1 PREVALENCE OF TYPE I AND II DIABETES: TOP SIX

COUNTRIES WITH HIGH GROWTH PROJECTIONS, THROUGH 2013

(MILLIONS)

TABLE 2 PREVALENCE OF TYPE II DIABETES: TOP SIX COUNTRIES

WITH PROJECTIONS, THROUGH 2013 (MILLIONS)

TABLE 3 DEFINITIONS OF THE FOUR TYPES OF DIABETES

TABLE 4 SUMMARY OF DIABETES PRODUCTS AND APPLICATIONS

TABLE 5 CAUSAL OR RISK FACTORS BY DIABETES TYPE

TABLE 6 COMPLICATIONS BY TYPE OF DIABETES

TABLE 7 FDA APPROVED CONTINUOUS GLUCOSE MONITORING

SYSTEMS BY MANUFACTURER

TABLE 8 FDA APPROVED INSULIN INFUSION PUMPS BY

MANUFACTURER

TABLE 9 PROJECTED MARKET LEADER SALES OF CONTINUOUS

GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION

PUMPS, THROUGH 2013 ($ MILLIONS)

TABLE 10 TECHNOLOGICAL EVOLUTION OF INSULIN DELIVERY

METHODS

TABLE 11 FDA APPROVED INSULIN-DEPENDENT PRODUCTS BY

MARKET LEADER

TABLE 12 INSULIN-DEPENDENT DRUG SALES FORECAST BY

MANUFACTURER, THROUGH 2013 ($ MILLIONS)

TABLE 13 THE SEVEN CLASSES OF TYPE II DIABETES DRUGS

TABLE 14 FDA APPROVED BRAND-NAME SULFONYLUREA DRUGS BY

DRUGMAKER

TABLE 15 FDA APPROVED BRAND-NAME BIGUANIDE DRUGS

TABLE 16 FDA APPROVED BRAND-NAME ALPHA-GLUCOSIDASE

INHIBITOR DRUGS

TABLE 17 FDA APPROVED BRAND-NAME MEGLITINIDE DRUGS

TABLE 18 FDA APPROVED BRAND-NAME THIAZOLIDINEDIONES

DRUGS

TABLE 19 FDA APPROVED BRAND-NAME INCRETIN MIMETICS

DRUGS

TABLE 20 FDA APPROVED BRAND-NAME DPP-4 DRUGS

TABLE 21 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT

DRUG FORECAST, THROUGH 2013 ($ MILLIONS)

TABLE 22 THE MARKET FOR NEW CLASSES OF DIABETES

TREATMENTS

TABLE 23 DRUGS USED TO TREAT COMMON DIABETIC

COMPLICATIONS BY MANUFACTURER

TABLE 24 FORECAST OF TOP SELLING DRUGS USED IN THE

TREATMENT OF COMMON DIABETIC COMPLICATIONS BY

MANUFACTURER, THROUGH 2013 ($ MILLIONS)

TABLE 25 FDA APPROVED GENERIC SULFONYLUREAS BY

MANUFACTURER

TABLE 26 FDA APPROVED GENERIC BIGUANIDES BY

MANUFACTURER

TABLE 27 FDA APPROVED GENERIC MEGLITINIDES BY

MANUFACTURER

TABLE 28 FDA APPROVED GENERIC THIAZOLIDINEDIONES BY

MANUFACTURER

TABLE 29 TOP SELLING GENERIC ANTIDIABETIC DRUG FORECAST, THROUGH 2013 ($ MILLIONS)

TABLE 30 DIABETES DRUGS IN PHASE I CLINICAL TRIALS

TABLE 31 DIABETES DRUGS IN PHASE II CLINICAL TRIALS

TABLE 32 DIABETES DRUGS IN PHASE III CLINICAL TRIALS

TABLE 33 DIABETES DRUGS IN PHASE IV CLINICAL TRIALS

TABLE 34 COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS

TABLE 35 COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS

TABLE 36 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPE I AND TYPE II DIABETES

TABLE 37 PHASE I CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

TABLE 38 PHASE II CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

TABLE 39 PHASE III CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

TABLE 40 PHASE IV CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

TABLE 41 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS

TABLE 42 WORLDWIDE SHARES OF PATENTS AND PUBLISHED PATENT APPLICATIONS ON TYPE I AND TYPE II DIABETES TREATMENTS BY SELECTED COUNTRY, 1/1/2001-11/1/2007 (NUMBER)

TABLE 43 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE I DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 44 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE II DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991 TO 11/30/2007 (NUMBER)

TABLE 45 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 46 U.S. AND EUROPEAN SHARES OF PATENTS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 47 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SITAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 48 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON VILDAGLIPTIN BY PATENT HOLDER, 1/1/2001-1/1/2007 (NUMBER)

TABLE 49 U.S. PATENT SHARES OF VILDAGLIPTIN BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 50 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SAXAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 51 U.S. PATENT SHARES OF LIRAGLUTIDE BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 52 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON TESAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 53 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON MURAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)

TABLE 54 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS, 1/1/1991-11/30/2007 (NUMBER)

TABLE 55 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN INFUSION PUMPS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 56 U.S. AND EUROPEAN SHARES OF PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 57 U.S. AND EUROPEAN SHARES OF PATENTS ON BLOOD GLUCOSE METERS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)

TABLE 58 INHALED INSULIN PRODUCTS UNDER DEVELOPMENT BY

COMPANY

TABLE 59 INSULIN DISPENSING PATCHES BY MANUFACTURER

LIST OF FIGURES

SUMMARY FIGURE GLOBAL DIABETES MARKET FORECAST BY

SEGMENT, 2006-2013 ($ BILLIONS)

FIGURE 1 PROJECTED MARKET LEADER SALES OF CONTINUOUS

GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION

PUMPS, 2006-2013 ($ MILLIONS)

FIGURE 2 INSULIN-DEPENDENT DRUG SALES FORECAST BY

MANUFACTURER, 2006-2013 ($ MILLIONS)

FIGURE 3 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT

DRUG FORECAST, 2006-2013 ($ MILLIONS)

FIGURE 4 FORECAST OF TOP SELLING DRUGS USED IN THE

TREATMENT OF COMMON DIABETIC COMPLICATIONS BY

MANUFACTURER, 2006-2013 ($ MILLIONS)